DefinitionThis section has been translated automatically.
Peripheral vasodilator.
Half-lifeThis section has been translated automatically.
1–1,5 h
You might also be interested in
IndicationThis section has been translated automatically.
Claudication intermittens, peripheral arterial circulatory problems.
Limited indicationThis section has been translated automatically.
Pregnancy, lactation, severe cardiac arrhythmia, coronary sclerosis, renal insufficiency, cerebral sclerosis.
Dosage and method of useThis section has been translated automatically.
- Peroral application: Initially 200-400 mg p.o. 3 times/day, later on 100 mg 3 times/day if necessary. Alternatively: Initially 2 times/day 600 mg retard form p.o., later possibly 2 times/day 400 mg.
- Intravenous application: Initial 100 mg in 300 ml 0.9% NaCl solution within 90-180 min. i.v., increase by 100 mg/day up to max. 1.2 g.
Undesirable effectsThis section has been translated automatically.
Dyspnoea, BB changes, gastrointestinal disorders, cholestasis, hepatitis, dry mouth, allergic reactions, vasculitis, cardiac arrhythmia, tachycardia, headaches, confusion, dizziness, visual and hearing disorders, polydipsia, shock.
InteractionsThis section has been translated automatically.
See Table 1.
ContraindicationThis section has been translated automatically.
Hypersensitivity to methylxanthines, severe arteriosclerosis, acute bleeding, fresh myocardial infarction, extensive retinal bleeding, peptic ulcer.
PreparationsThis section has been translated automatically.
Trental, pentoxifyllin-ratiopharm
TablesThis section has been translated automatically.
Major drug interactions of pentoxifylline
ACE inhibitors |
RR drop ↑ |
Antihypertensives |
RR drop ↑ |
β -receptor blockers |
RR decline ↑ |
Calcium antagonists |
RR decline ↑ |
Coumarins |
Bleeding tendency |
Diuretics |
RR drop ↑ |
Heparin |
Bleeding tendency |
Insulin |
|
Prof. Dr. med. Peter Altmeyer